• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    2/12/24 4:06:57 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    SC 13G/A 1 d760465dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    LUMIRADX LIMITED

    (Name of Issuer)

    Common Shares, par value $0.0000028 per share

    (Title of Class of Securities)

    G5709L109

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G5709L109    13G    Page 2 of 5 Pages

     

    1.   

    NAMES OF REPORTING PERSONS

     

    Petrichor Healthcare Capital Management LP

    2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a) ☐  (b) ☒

    3.   

    SEC USE ONLY

     

    4.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH    5.   

    SOLE VOTING POWER

     

    0

       6.   

    SHARED VOTING POWER

     

    1,092,098 (1)

       7.   

    SOLE DISPOSITIVE POWER

     

    0

       8.   

    SHARED DISPOSITIVE POWER

     

    1,092,098 (1)

    9.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,092,098 (1)

    10.   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.7% (2)

    12.   

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

    (1)

    Consists of 788,914 Common Shares (as defined herein) issuable upon the exercise of Common warrants of the Issuer (as defined herein) held by Petrichor (as defined herein), and 303,184 Common Shares issuable upon the conversion of A Ordinary warrants of the Issuer held by Petrichor.

    (2)

    The percentage set forth in Row 11 of this Cover Page is based on 154,224,500 Common Shares outstanding as of December 31, 2022, as reported on the Form 20-F filed by the Issuer with the Securities and Exchange Commission on May 1, 2023.


    CUSIP No. G5709L109    13G    Page 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

    LumiraDx Limited

     

      (b)

    Address of Issuer’s principal executive offices

    c/o Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108 Cayman Islands

    Item 2.

     

      (a)

    Name of person filing

    This Schedule 13G is being filed on behalf of Petrichor Healthcare Capital Management LP (“Petrichor”) with respect to the Common Shares, $0.0000028 par value per share (the “Common Shares”), of LumiraDx Limited, a Cayman Islands exempted company (the “Issuer”).

     

      (b)

    Address or principal business office or, if none, residence

    220 East 42nd Street, New York, NY 10017

     

      (c)

    Citizenship

    See Row 4 of the Cover Page.

     

      (d)

    Title of class of securities

    Common Shares, par value $0.0000028 per share

     

      (e)

    CUSIP No.

    G5709L109

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)   ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b)   ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c)   ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d)   ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         (e)   ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)   ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g)   ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h)   ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)   ☐    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k)   ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).


    CUSIP No. G5709L109    13G    Page 4 of 5 Pages

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

    Item 4. Ownership.

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. G5709L109    13G    Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 12, 2024

     

    PETRICHOR HEALTHCARE CAPITAL MANAGEMENT LP
    By:   /s/ Tadd S. Wessel
    Tadd S. Wessel, Chief Executive Officer
    Get the next $LMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

      LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

      10/27/23 4:45:02 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Raymond James reiterated coverage on LumiraDx with a new price target

      Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      3/11/22 7:22:18 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Evercore ISI Group initiated coverage on LumiraDx with a new price target

      Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

      11/15/21 8:56:20 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on LumiraDx with a new price target

      BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

      10/27/21 8:35:45 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Financials

    Live finance-specific insights

    See more
    • LumiraDx Reports Second Quarter 2023 Results

      LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

      8/24/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

      LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

      8/16/23 4:30:00 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Reports First Quarter 2023 Results

      LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

      5/16/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/12/24 4:06:57 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/9/24 4:16:20 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

      SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

      12/29/23 1:52:49 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    SEC Filings

    See more
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      2/6/24 4:34:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/29/23 4:26:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/8/23 7:15:38 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care